Head-to-head · Cost-Efficiency Index
Sprout Health vs Eden
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Sprout Health
Price-first shoppers who want a fast, low-friction signup (often no labs or visit) at a verified pharmacy and don't need a named medical director.
Visit Sprout HealthEden
People who will trade a higher sticker price for verified nationwide access and stronger clinical oversight.
Visit EdenThe verdict
Eden takes it, leading the Cost-Efficiency Index 86 to 85. You pay a premium per month, but you buy back certainty: all-50 access and high-disclosure clinical oversight that hold their value. Sprout Health still earns a B — Price-first shoppers who want a fast, low-friction signup (often no labs or visit) at a verified pharmacy and don't need a named medical director.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Eden.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Sprout Health | Eden |
|---|---|---|
| Cost-Efficiency Index | 85/100 | 86/100 |
| Semaglutide / mo | $149/mo | $239/mo |
| Tirzepatide / mo | $199/mo | $349/mo |
| Semaglutide / yr (modeled) | $1,788 | $2,868 |
| Tirzepatide / yr (modeled) | $2,388 | $4,188 |
| Coverage | Most states | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #9 | #15 |
Sprout Health
85/100Where the value is
- Well-priced compounded — $149 semaglutide / $199 tirzepatide — with LegitScript certification behind it
- Low-friction intake: no labs and often no synchronous visit required
- Offers a brand-name Wegovy/Zepbound path alongside the compounded route
The tradeoffs
- No named medical director published, so clinical oversight is harder to attribute
- Availability is quiz-gated by state, so nationwide access isn't guaranteed until you qualify
Regulatory note: the FDA issued a warning letter to Sprout Health Partners LLC dba Sprout Health in September 2025. We still list and link to Sprout Health; you should know the letter is on the public record before you decide.
Eden
86/100Where the value is
- High transparency — clear supply-chain and clinician disclosure lowers hidden-cost risk
- Nationwide availability with both molecules disclosed
- Strong clinical oversight adds value beyond the raw price
The tradeoffs
- Premium per-month cost drags its normalized value score
- Compounded only — no brand-name access
Regulatory note: the FDA issued a warning letter to Eden Health International Inc. dba Eden in June 2026. We still list and link to Eden; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.